AI Trust Score, Reviews & Company Verification
Is this your company? Claim the Element Biosciences profile to verify ownership and manage company-provided details.
Independent company assessment
9.1/10A · Exceptional
35 indexed evidence signals reviewed
AI Comparison
Mixed Consensus72% Confidence
Based on 5 polled AI models
- GeminiGoogle DeepMindMixed80%Confidence
- GrokxAIMixed72%Confidence
- DeepSeekDeepSeekMixed68%Confidence
- GLMZ.aiMixed68%Confidence
This profile is waiting for Element Biosciences
Element Biosciences has not claimed this ShouldEye profile yet.
Until an authorized representative verifies ownership, ShouldEye AI independently maintains this overview from public records, reviews, regulatory filings, and live trust signals. Nothing on this page has been approved by the brand.
- Respond to reviews and experiences in your voice
- Replace this placeholder with your official brand message
- Take control of how your trust score is presented
Free verification for authorized company representatives
Element Biosciences develops genomic sequencing and multiomics platforms that deliver high-quality, affordable sequencing for biological research, drug discovery, and diagnostic applications.
- Headquarters
- US
Full intelligence report for Element Biosciences
Element Biosciences maintains rigorous regulatory compliance and transparent privacy and legal frameworks that underscore disciplined corporate operations. Strong review sentiment and responsive customer service indicate users generally experience reliable, satisfactory engagement. Softer performance in domain integrity and reputation leaves minor headroom for strengthening digital security posture and broader market confidence, but the overall trust profile remains robust and verified.
- ISO 13485 certification demonstrating robust quality management system
- No direct regulatory enforcement actions or findings of fraud/unfair business practices
- Proactive assertion of intellectual property rights and successful defense in a German patent case
- Multiple active patent infringement lawsuits from major competitors (Illumina, 10x Genomics) creating legal and financial exposure
- Allegations of leveraging former employees' knowledge from competitors in product development
- Weaknesses in the company’s own patent portfolio, with 45% of applications flagged for patentability issues
Public-facing leadership and ownership signals for Element Biosciences — synthesized from verified profiles and corporate disclosures where available.